Resolvin E2
Based on 1 Customer Validation
Resolvin E2 ((-)-Resolvin E2) is an endogenous lipid mediator produced from eicosapentaenoic acid (EPA) under the catalysis of 5-lipoxygenase (5-LOX), and its production increases in hypoxic environments. Resolvin E2 antagonizes BLT1, partially activates ChemR23, and promotes ubiquitin-proteasome-mediated degradation of COX-2. Resolvin E2 reduces the production of prostaglandin E2, blocks polymorphonuclear leukocyte infiltration, and promotes the resolution of airway inflammation. Resolvin E2 ameliorates lipopolysaccharide (LPS) (HY-D1056)-induced depressive-like behaviors. Resolvin E2 can be used in research related to depression, murine peritonitis, neonatal asthma, and other conditions.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.5%
- CAS No.: 865532-70-3
- 화학식: C20H30O4
- 분자량:334.45
-
보관:
Solution, -20°C, 2 years
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
All Endogenous Metabolite Isoforms
MoreAll Leukotriene Receptor Isoforms
MoreAll Chemerin Receptor Isoforms
More
Biological Activity
Resolvin E2 (10 nM; 2-16 h) suppresses COX-2 protein expression in a time-dependent manner (significantly at 4-16 h) without altering COX-1 levels in human macrophage-like U937 cells[3].
Resolvin E2 (10 nM; 4-16 h) significantly reduces PGE2 production in human macrophage-like U937 cells[3].
Resolvin E2 (10 nM; 8 h) promotes COX-2 protein degradation via the ubiquitin-proteasome system in human macrophage-like U937 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human macrophage-like U937 cells (differentiated with phorbol 12-myristate 13-acetate)
-
Concentration:10 nM
-
Incubation Time:2 h, 4 h, 8 h, 16 h
-
Result:Did not alter COX-1 protein levels at any time point tested.
Suppressed COX-2 protein expression in a time-dependent manner, with statistically significant suppression observed at 4 h, 8 h, and 16 h compared to the 0 h control.
-
Cell Line:human macrophage-like U937 cells (differentiated with phorbol 12-myristate 13-acetate)
-
Concentration:10 nM
-
Incubation Time:2 h, 4 h, 8 h, 16 h
-
Result:Reduced PGE2 production in a time-dependent manner, with statistically significant suppression observed at 4 h, 8 h, and 16 h compared to the 0 h control.
-
Cell Line:human macrophage-like U937 cells (differentiated with phorbol 12-myristate 13-acetate)
-
Concentration:10 nM
-
Incubation Time:2 h, 4 h, 8 h, 16 h
-
Result:Did not suppress COX-2 mRNA expression at any time point tested, with no statistically significant differences compared to the 0 h control.
-
Cell Line:human macrophage-like U937 cells (differentiated with phorbol 12-myristate 13-acetate)
-
Concentration:10 nM (Resolvin E2); 0.3 μM (MG132 pretreatment)
-
Incubation Time:8 h (Resolvin E2); 30 min (MG132 pretreatment)
-
Result:Suppressed COX-2 protein expression when administered alone.
Had its COX-2 protein expression suppression abrogated by pretreatment with 0.3 μM MG132, which restored COX-2 protein levels to a similar level as the untreated control.
Resolvin E2 (1-100 ng; intravenous injection, intraperitoneal injection; single administration) potently reduces human neutrophils (PMN) infiltration in zymosan-induced murine peritonitis[2].
Resolvin E2 (300 ng/mouse; intranasal administration; once daily for 3 consecutive days) alleviates neonatal asthma in high-risk pups by reducing airway eosinophilia, pulmonary tissue infiltration, and allergenic cytokine levels[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male, 11-12 weeks old, LPS-induced depression model)[1]
-
Dosage:1 ng; 10 ng
-
Administration:i.c.v.; single infusion
-
Result:Dose-dependently decreased LPS-induced increases in immobility time in the tail suspension test.
Significantly suppressed LPS-induced increases in immobility time in the forced swim test at the 10 ng i.c.v. dose.
Had no effect on immobility time in saline-injected control mice in either tail suspension or forced swim tests.
Did not affect locomotor activity or anxiety-like behavior (time spent in the center of an open field chamber) in either LPS-challenged or saline-injected mice.
-
Animal Model:FVB (male, 6-8 weeks old, peritonitis induced by intraperitoneal injection of 1 mg zymosan A in 1 mL saline)[2]
-
Dosage:1 ng (i.v., side-by-side comparison); 10 ng (i.v., side-by-side comparison); 100 ng (i.v., side-by-side comparison); 10 ng (i.v., route comparison); 10 ng (i.p.)
-
Administration:i.v.; single dose; i.p.; single dose
-
Result:Reduced PMN infiltration by 11.3% compared to controls.
Reduced PMN infiltration by 17.7% compared to controls.
Reduced PMN infiltration by 33.7% compared to controls.
Reduced PMN infiltration by 47.6% compared to controls.
Reduced PMN infiltration by 34.5% compared to controls.
Combined with 10 ng Resolvin E1 (i.v.) reduced PMN infiltration additively.
Showed potency not significantly different from Resolvin E1 at any tested dose.
-
Animal Model:BALB/c (neonatal, offspring of time-pregnant E13 BALB/c dams; neonatal asthma model induced by maternal gestational exposure to CAPs/DEPs (concentrated urban air particles and diesel exhaust particles) at E14-E20, followed by neonatal OVA (HY-W250978) sensitization and challenge)[4]
-
Dosage:300 ng/mouse
-
Administration:i.n.; once daily; 3 days
-
Result:Reduced BAL eosinophil counts by more than half and eosinophil percentages by ~20% in offspring of CAP- or DEP-exposed dams compared to untreated at-risk pups.
Decreased BAL IL-5 levels in offspring of DEP-exposed dams.
Decreased BAL IL-13 levels in offspring of DEP-exposed dams.
Decreased serum IL-5 levels in offspring of CAP-exposed dams.
Ameliorated lung tissue inflammatory infiltration compared to untreated at-risk pups.
Showed no effect in offspring of PBS-exposed control dams.
Chemical Information
-
CAS No. 865532-70-3
-
Appearance Liquid
-
분자량 334.45
-
화학식 C20H30O4
-
Color Colorless to light yellow
-
SMILES
CC[C@@H](O)/C=C/C=C\C/C=C\C/C=C\C=C\[C@@H](O)CCCC(O)=O
-
Synonyms
(-)-Resolvin E2
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Solution, -20°C, 2 years
순도&문서
-
Data Sheet (273 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Deyama S, et al. Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23. Psychopharmacology (Berl). 2018;235(1):329-336. [Content Brief]
[2]. Tjonahen E, et al. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol. 2006;13(11):1193-1202. [Content Brief]
[3]. Hamaguchi A, et al. Resolvin E1 and Resolvin E2 suppress cyclooxygenase-2 expression through ubiquitin-proteasome-mediated degradation in human macrophage-like U937 cells. Prostaglandins Other Lipid Mediat. 2026;183:107064. [Content Brief]
[4]. Ramar M, et al. Intra-Airway Treatment with Synthetic Lipoxin A4 and Resolvin E2 Mitigates Neonatal Asthma Triggered by Maternal Exposure to Environmental Particles. Int J Mol Sci. 2023;24(7):6145. Published 2023 Mar 24. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Resolvin E2 Related Classifications
HY-133159 Related Classifications
Powered by Bioz
- Resolvin E2
- 865532-70-3
- (-)-Resolvin E2
- Resolvin E 2
- Resolvin E-2
- Endogenous Metabolite
- Leukotriene Receptor
- Chemerin Receptor
- COX
- Lipoxygenase
- COX-1
- murine models
- BLT1
- ChemR23
- neonatal asthma
- eicosapentaenoic acid
- cyclooxygenase-2
- human macrophage-like U937 cells
- ubiquitin-proteasome system
- human neutrophils
- Inhibitor
- inhibitor
- inhibit